Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Arthritis Res Ther ; 16(3): R134, 2014 Jun 25.
Article in English | MEDLINE | ID: mdl-24964765

ABSTRACT

INTRODUCTION: Post-traumatic arthritis (PTA) is a progressive, degenerative response to joint injury, such as articular fracture. The pro-inflammatory cytokines, interleukin 1(IL-1) and tumor necrosis factor alpha (TNF-α), are acutely elevated following joint injury and remain elevated for prolonged periods post-injury. To investigate the role of local and systemic inflammation in the development of post-traumatic arthritis, we targeted both the initial acute local inflammatory response and a prolonged 4 week systemic inflammatory response by inhibiting IL-1 or TNF-α following articular fracture in the mouse knee. METHODS: Anti-cytokine agents, IL-1 receptor antagonist (IL-1Ra) or soluble TNF receptor II (sTNFRII), were administered either locally via an acute intra-articular injection or systemically for a prolonged 4 week period following articular fracture of the knee in C57BL/6 mice. The severity of arthritis was then assessed at 8 weeks post-injury in joint tissues via histology and micro computed tomography, and systemic and local biomarkers were assessed in serum and synovial fluid. RESULTS: Intra-articular inhibition of IL-1 significantly reduced cartilage degeneration, synovial inflammation, and did not alter bone morphology following articular fracture. However, systemic inhibition of IL-1, and local or systemic inhibition of TNF provided no benefit or conversely led to increased arthritic changes in the joint tissues. CONCLUSION: These results show that intra-articular IL-1, rather than TNF-α, plays a critical role in the acute inflammatory phase of joint injury and can be inhibited locally to reduce post-traumatic arthritis following a closed articular fracture. Targeted local inhibition of IL-1 following joint injury may represent a novel treatment option for PTA.


Subject(s)
Interleukin-1/metabolism , Knee Injuries/metabolism , Knee Joint/metabolism , Tumor Necrosis Factor-alpha/metabolism , Animals , Antirheumatic Agents/administration & dosage , Antirheumatic Agents/blood , Antirheumatic Agents/pharmacology , Arthritis, Experimental/etiology , Arthritis, Experimental/metabolism , Arthritis, Experimental/prevention & control , Etanercept , Fractures, Closed/complications , Immunoglobulin G/administration & dosage , Immunoglobulin G/blood , Immunoglobulin G/pharmacology , Inflammation Mediators/antagonists & inhibitors , Inflammation Mediators/metabolism , Injections, Intra-Articular , Interleukin 1 Receptor Antagonist Protein/administration & dosage , Interleukin 1 Receptor Antagonist Protein/blood , Interleukin 1 Receptor Antagonist Protein/pharmacology , Interleukin-1/antagonists & inhibitors , Intra-Articular Fractures/complications , Knee Injuries/etiology , Knee Injuries/prevention & control , Knee Joint/drug effects , Knee Joint/pathology , Male , Mice, Inbred C57BL , Receptors, Tumor Necrosis Factor/administration & dosage , Receptors, Tumor Necrosis Factor/blood , Synovitis/metabolism , Synovitis/prevention & control , Treatment Outcome , Tumor Necrosis Factor-alpha/antagonists & inhibitors , X-Ray Microtomography
SELECTION OF CITATIONS
SEARCH DETAIL